Palisade Bio (PALI) Corporate presentation summary

Mission and corporate highlights

• Focused on developing next-generation, once-daily, oral PDE4 inhibitor prodrugs for inflammatory and fibrotic diseases, targeting the multi-billion-dollar IBD market.

• Lead asset PALI-2108 is the only oral PDE4 inhibitor prodrug in development for ulcerative colitis (UC) and Crohn's disease (CD), with precision medicine CDx test in development to identify responders.

• Raised $138 million from institutional healthcare investors, with $132.6 million cash as of March 31, 2026, sufficient to fund major clinical milestones.

Product differentiation and mechanism

• PALI-2108 is a potent, gut-activated PDE4 inhibitor prodrug with 10–20x potency over other PDE4 inhibitors, targeting the terminal ileum and colon.

• Localized bioactivation in the GI tract minimizes systemic exposure and side effects, improving tolerability and enabling once-daily dosing.

• Dual anti-inflammatory and anti-fibrotic action, with potential for combination therapies and improved patient outcomes.

Clinical development and milestones

• Positive Phase 1a/b data in UC and FSCD (fibrostenosing Crohn's disease) demonstrated safety, tolerability, and pharmacokinetics supporting local bioactivation.

• Phase 2 studies in UC and CD expected to commence in 2026/27, with key milestones including IND clearance, first subject dosing, and primary efficacy readouts through 2028.

• Phase 1a/b studies showed no serious adverse events, excellent safety, and robust PK/PD profiles supporting daily dosing.